|Bid||93.35 x 900|
|Ask||93.97 x 1400|
|Day's range||92.45 - 94.08|
|52-week range||70.89 - 94.56|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||16.74|
|Earnings date||28 Jul 2022|
|Forward dividend & yield||2.76 (2.95%)|
|Ex-dividend date||14 Mar 2022|
|1y target est||96.06|
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Rates could spike sooner rather than later. Prepare your portfolio.
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.